Visual Outcomes in Patients with Diabetic Macular Edema Treated with Dexamethasone Implant in Routine Clinical Practice

• Published in: Acta clinica Croatica (Tisak) Vol. 60; no. 4; pp. 602 - 608
• Main Author: Urbančič, Mojca
• Format: Journal Article
• Language: English
• Published: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 01-12-2021; Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
• Subjects: Dexamethasone implant; Diabetic macular edema; Original Scientific Papers; Routine clinical practice
• ISSN: 0353-9466; 1333-9451
• DOI: 10.20471/acc.2021.60.04.06

The aim was to evaluate visual outcomes of the real-life usage of dexamethasone (DEX) implants in diabetic macular edema (DME) patients and evaluate the possible additional visual acuity (VA) gain with combined treatment. We retrospectively reviewed medical records of DME patients treated with DEX implants. The mean best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT) at baseline and one year were compared. BCVA improved from 58.4±14.9 letters at baseline to 62.4±14.5 letters at one-year evaluation (p=0.002). The mean change in BCVA was 5.2±11.1 letters. CRT decreased from 485.7±146.3 µm at baseline to 391.5±129.0 µm at one year (p<0.001). The mean change in CRT was -89.6±143.3 µm. Patients received a mean of 2.0±0.7 DEX implants. Study eyes were also divided into a group receiving DEX implant monotherapy and a group receiving DEX implant and vascular endothelial growth factor inhibitor (anti-VEGF) therapy. Changes in BCVA and CRT and the number of DEX implant injections were compared between the two groups. No difference in VA gain was found between the eyes receiving monotherapy and the eyes receiving combined treatment. In conclusion, DEX implant therapy was effective in gaining vision in DME patients. No additional VA gain was achieved with combined treatment.